文献速递胸部肿瘤

基于体积测量对接受免疫检查点抑制剂治疗的晚期非小细胞肺癌超进展的全面临床与遗传学特征分析

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor.
PubMed 文献 · J Thorac Oncol · 2019-06-11

该研究回顾性分析335例接受免疫检查点抑制剂单药治疗的晚期非小细胞肺癌患者,通过定量纵向比较基线与随访CT的肿瘤大小和体积来定义超进展,并匹配380基因深度测序结果。结果显示基于体积测量定义的超进展(HPDV)与更差的总生存显著相关,且治疗前衍生中性粒细胞与淋巴细胞比值>4、乳酸脱氢酶高于正常上限及STK11与KRAS突变共存可能与HPDV相关。

要点

  • 基于体积测量定义超进展比基于RECIST 1.1一维分析更精确。
  • HPDV患者中位OS为4.7个月,非HPDV进展患者为7.9个月,差异显著(P=0.004)。
  • 治疗前衍生中性粒细胞与淋巴细胞比值>4、乳酸脱氢酶高于正常上限与HPDV显著相关。

核心结论

  • 基于体积测量定义免疫检查点抑制剂治疗后的超进展比基于一维RECIST分析更精确。
  • 治疗前衍生中性粒细胞与淋巴细胞比值、乳酸脱氢酶水平及STK11与KRAS突变共存可作为超进展预测的潜在生物标志物。

研究设计与样本

  • 回顾性分析335例接受免疫检查点抑制剂单药治疗的晚期非小细胞肺癌患者的临床与影像学资料。
  • 对基线与随访计算机断层扫描结果进行肿瘤大小和体积的定量纵向分析,并与380基因深度测序的个体基因组图谱匹配。

主要发现

  • 在135例按RECIST 1.1评估为进展的患者中,基于体积测量发现48例超进展(占全部患者14.3%,占进展患者35.6%),基于RECIST 1.1评估发现44例超进展(占全部患者13.1%,占进展患者32.6%)。
  • HPDV患者的中位总生存为4.7个月(95%CI:3.5-11.9),非HPDV进展患者为7.9个月(95%CI:6.0-13.5),差异有统计学意义(P=0.004)。
  • 基于RECIST 1.1定义的超进展患者与非超进展患者的总生存无差异。
  • HPDV状态是总生存的独立影响因素。
  • 衍生中性粒细胞与淋巴细胞比值>4和乳酸脱氢酶高于正常上限与HPDV显著相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Hyperprogressive disease (HPD), characterized by accelerated tumor progression, has been proposed as a new pattern of progression after immune checkpoint inhibitor (ICI) treatment. The aim of this study was to describe the characteristics of HPD and investigate its predictive markers. METHODS: Clinical and radiological findings of 335 patients with advanced NSCLC treated with ICI monotherapy were retrospectively analyzed. Radiological data were quantitatively and longitudinally analyzed for tumor size and volume by comparing baseline and follow-up computerized tomography results. The findings were matched with individual genomic profiles generated by deep sequencing of 380 genes. RESULTS: Among 135 patients with progressive disease (PD), as assessed by the Response Evaluation Criteria in Solid Tumors version 1.1 criteria, 48 (14.3% of all patients and 35.6% of those with PD) and 44 (13.1% of all patients and 32.6% among those with PD) were found to have HPD by volumetry (HPDV) and assessed by RECIST 1.1 (HPDR), respectively. Patients with HPDV were associated with significantly inferior overall survival (OS) versus that of patients without HPDV with PD (median OS = 4.7 months [95% confidence interval: 3.5-11.9)] versus 7.9 months [95% confidence interval: 6.0-13.5] [p = 0.004]); OS did not differ between patients without and without HPDR. HPDV status was an independent factor in OS. A derived neutrophil-to-lymphocyte ratio greater than 4 and lactate dehydrogenase level greater than the upper limit of normal were significantly associated with HPDV. Moreover, we identified coinciding KRAS and serine/threonine kinase 11 gene (STK11) mutations in the cohort of patients with HPDV (three of 16), whereas none were found in the cohort of patients without HPDV (zero of 28). CONCLUSIONS: Defining HPD treated with ICI on the basis of volumetric measurement is more precise than is defining it on the basis of one-dimensional analysis. Pre-ICI derived neutrophil-to-lymphocyte ratio, lactate dehydrogenase level, and concurrence of STK11 and KRAS mutations could thus be used as potential biomarkers for HPD prediction.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Kim Y, Kim CH, Lee HY, et al. Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. J Thorac Oncol. 2019. PMID: 31195179. doi:10.1016/j.jtho.2019.05.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。